While the sample size of patients analyzed post neoadjuvant therapy is very small, these findings may implicate HER3 as a feedback mechanism that is not related to a particular systemic therapy, but rather inherent to the tumor biology which may ultimately lead to treatment resistance. Here, ERBB3 is linked to neoplasm.